Browse News

Found 61 articles

• Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/8/2023

  Vaxxinity, Inc. today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

• 

  Araclon’s Alzheimer’s Vaccine Shows Clean Safety Profile in Phase II Analysis

  10/25/2023

  While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.

• Vaxxinity to Present at Upcoming Investor Conferences in September 2023

  8/29/2023

  Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September.

• Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)

  8/22/2023

  Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023.

• Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

  8/10/2023

  Vaxxinity, Inc. announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild Alzheimer’s disease.

• Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/9/2023

  Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

• Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

  7/27/2023

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.

• Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients

  7/17/2023

  Vaxxinity, Inc. today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays.

• Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

  6/22/2023

  Vaxxinity, Inc. today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.

• Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/9/2023

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

  3/28/2023

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.

• Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

  3/27/2023

  Vaxxinity, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

  3/20/2023

  Vaxxinity, Inc. today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401.

• Vaxxinity to Present at Upcoming March Scientific and Medical ConferencesVaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference

  3/2/2023

  Vaxxinity, Inc. today announced that its scientists and executives will present at three upcoming scientific and medical conferences in March.

• Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

  2/2/2023

  Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla.

• Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference

  1/5/2023

  Vaxxinity, Inc. announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 3 p.m. ET.

• Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

  12/2/2022

  Vaxxinity, Inc. (Nasdaq: VAXX) announced today that its next generation UB-612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase 3 trial.

• Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/10/2022

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the third quarter ended September 30, 2022.

• Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022

  11/3/2022

  Vaxxinity, Inc. announced that it will host its first in-person and virtual Analyst and R&D Day in New York on Thursday, November 10, 2022 from 8:30 a.m. to 12:30 p.m. ET.

• Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

  10/24/2022

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that enrollment is complete for its global Phase 3 pivotal trial evaluating UB-612 as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary series vaccinations.